

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sinohealth Holdings Limited

中康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2361)

SUPPLEMENTAL ANNOUNCEMENT ON THE STATUS OF THE PUBLIC FLOAT

Reference is made to the announcement of the Company dated 21 January 2026 in relation to the status of the public float of the Company and the announcement of the Company dated 15 January 2026 in relation to the grant of share awards under the Share Award Scheme (the “**Announcements**”). Unless otherwise specified, capitalized terms used herein shall have the same meanings as defined in the Announcements.

The Board wishes to clarify that the Company’s public float as of the date of the Announcement was 16.45%, which was below the minimum prescribed public float (“**Initial Prescribed Threshold**”) of 25% as prescribed by Rule 13.32B(1) of the Listing Rules. This was because 39,958,477 Shares (representing approximately 8.84% of the total issued share capital of the Company as of the date of the Announcement), which represent share awards not yet granted and held by Futu Trustee Limited as the trustee of the Share Award Scheme, were not counted toward the public float of the Company.

The Board would like to supplement the following information in relation to the Company’s proposals to restore its public float:

In line with the Company’s strategic development and the performance attainment of Eligible Participants, the Company expects to complete the grant of Share Awards currently available within the next three years. The details of the plan are as follows:

- (i) as at the date of this announcement, the Share Awards available for grant represent 8.84% of the Company’s total share capital. The Company will, taking into account the achievement of its annual operating targets for each of the next three years in 2026, 2027 and 2028, as well as the comprehensive appraisal results of the incentive recipients, aim to grant no less than 2% of the total share capital in Shares each year to non-core connected persons of the Company; and
- (ii) the granting of the Company’s Share Awards will be determined based on a combination of indicators at both the company level and the individual level of the Eligible Participants. The objective is to motivate the Grantees to drive the Company’s development on a medium-to-long-term basis, so as to maximize the effectiveness of the Share Awards.

Taking into account strategic development and market conditions, the Company intends to further increase its public float through multiple channels, with specific plans including:

- (a) completing an equity financing to expand the Company's share capital; and/or
- (b) proactively communicating with major shareholders to discuss arrangements for such major shareholders to sell part of their shareholdings to independent third parties in order to restore the Company's public float.

Following the disclosure of the 2025 annual results, the Company will, on one hand, actively seek suitable placing agents and other relevant service providers and, on the other hand, simultaneously initiate communication with the Company's major shareholders and potential investors to advance the implementation of the aforementioned plan. Considering the volatility of the capital markets, the processes of engaging with potential investors, negotiating transaction terms and obtaining the necessary approvals will require time. The Company expects, through the plans as set out in sub-paragraphs (a) and/or (b) above, to achieve an increase in the public float of no less than 8 percentage points by the end of June 2027.

Based on the Company's overall plans to restore its public float as set out above in sub-paragraphs (i), (ii), (a) and (b), the Company expects to meet the Initial Prescribed Threshold as prescribed by Rule 13.32(B)(1) of the Listing Rules by the end of June 2027.

For so long as the Company remains non-compliant with Rule 13.32B of the Listing Rules, the Company will continue to:

- (i) provide regular update on the public float status and its public float restoration plan. Announcement(s) will be made by the Company on a monthly basis until the public float of the Company is restored in accordance with the Listing Rules, so as to keep shareholders of the Company and the market informed on the progress made in carrying out the public float restoration plans; and
- (ii) observe other requirements under Rule 13.32E of the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By Order of the Board
Sinohealth Holdings Limited
Wu Yushu
Chairman

Hong Kong, 9 February 2026

As at the date of this announcement, the executive Directors are Mr. Wu Yushu and Ms. Wang Lifang, the non-executive Director is Mr. Fu Haitao, and the independent non-executive Directors are Ms. Wang Danzhou, Ms. Chui Hoi Yam and Mr. Wei Bin.